Ema

EU ombudsman takes issue with trial transparency moves by EMA

EU ombudsman takes issue with trial transparency moves by EMA

By Zachary Brennan

In a letter to the EMA (European Medicines Agency), the European Ombudsman Emily O'Reilly has expressed concern that a significant change of policy on trial data transparency could limit the amount of data that becomes available.

Spotlight

Follow us

Featured Events

View more

Products

View more

Webinars

Featured Suppliers

All suppliers